Abstract
>60 ml/min/1.73 m 2 . The study drugs were discontinued in 23.7% (ramipril), 21.0% (telmisartan) and 29.4% (combined) of the patients, respectively. Symptomatic hypotension was documented more often in the combined group (406 vs. 149 in ramipril). The primary outcome of cardiovascular (CV) death, myocardial infarction (MI), stroke or hospitalization for heart failure occurred after 56 months in 16.5% (ramipril), in 16.7% (telmisartan) and in 16.3% (combined) in the three groups, respectively. The primary renal outcome of dialysis, a doubling of serum creatinine and all deaths was 13.5% (ramipril), 13.4% (telmisartan) and 14.5% (combined) in the three groups, respectively. Excluding the initial eGFR decline, which accounted for about 70% of the overall decline, the overall decrease in eGFR was −1.17 (ramipril), −2.06 (telmisartan) and −2.49 ml/min/1.73 m 2 (combined). The incidence of chronic dialysis (n = 98) was similar among the groups, although acute dialysis was more frequent in the combined group (28% vs.13% in the ramipril and 13.4% in the telmisartan group).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
